Science and Technology Science and Technology
Sat, February 15, 2025
Fri, February 14, 2025
Thu, February 13, 2025
Wed, February 12, 2025
Tue, February 11, 2025
[ Tue, Feb 11th ] - techUK
AI Action Summit: Day 4
Mon, February 10, 2025
Sun, February 9, 2025
Sat, February 8, 2025
Fri, February 7, 2025
[ Fri, Feb 07th ] - STAT
Signs of life at the CDC
Thu, February 6, 2025
[ Thu, Feb 06th ] - Vanguard
Solar power to the rescue
Wed, February 5, 2025
Tue, February 4, 2025
[ Tue, Feb 04th ] - Yahoo
Space Coast launch schedule
[ Tue, Feb 04th ] - NextBigFuture
Real Life Angry Birds

Oncocyte secures $29.1 million to advance FDA assay


//science-technology.news-articles.net/content/2 .. e-secures-29-1-million-to-advance-fda-assay.html
Published in Science and Technology on Monday, February 10th 2025 at 10:02 GMT by MSN   Print publication without navigation

  • IRVINE, Calif. - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, has announced a funding round led by existing investors, including strategic partner Bio-Rad Laboratories, Inc. (NYSE: NYSE:BIO),

Oncocyte Corporation has successfully raised $29.1 million through a private placement of common stock and warrants, aimed at advancing its FDA-cleared VitaGraft™ Kidney assay. This financial boost will support the company's efforts to expand its product offerings in the transplant monitoring sector. The VitaGraft Kidney assay, which measures donor-derived cell-free DNA (dd-cfDNA) to assess kidney transplant health, has already received FDA clearance and is designed to help clinicians detect rejection early, potentially improving patient outcomes. The funds will also be used for general corporate purposes, including working capital and further development of Oncocyte's diagnostic pipeline.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/oncocyte-secures-29-1-million-to-advance-fda-assay/ar-AA1yKVrB ]

Publication Contributing Sources

Similar Science and Technology Publications